Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy
Abstract
Immune checkpoint inhibitors (ICIs) are now a first-line treatment option for patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab. Mesothelioma has a low tumor mutation burden and no robust predictors of survival with ICI. Since ICIs enable adaptive antitumor immune responses, we investigated T-cell receptor (TCR) associations with survival in participants from two clinical trials treated with ICI.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2023
- Source ID
- 10.1136/jitc-2022-006035
Entities
People
- Aakash P Desai
- Aaron Mansfield
- Alexa Mccune
- Alireza Agahi
- Farhad Kosari
- George Vasmatzis
- Giannoula Karagouga
- James Smadbeck
- Janet Schaefer-klein
- John Cheville
- Julia Udell
- Jun Yin
- Maria Disselhorst
- Mitesh J. Borad
- Paul Baas
- Sarah H Johnson
- Stephen Murphy
- Tobias Peikert
Organizations
- National Cancer Institute
- The Mark Foundation for Cancer Research
- United States Department of Defense